[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fundación Española de Hematología y Hemoterapía\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":127},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,39,71,99],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100446416","spanish-registry-of-patients-with-igm-monoclonal-gammopathies-100446416",false,"NCT05093153","Spanish Registry of Patients With IgM Monoclonal Gammopathies","Spanish Registry of Patients With Diagnosis of IgM-MGUS, Asymptomatic & Symptomatic Waldenström Macroglobulinemia. Analysis of Clinical and Laboratory Features, Treatment and Outcomes.","PRAME","Inclusion Criteria:\n\n* Age ≥18 years\n* Patients having a confirmed diagnosis of either in the las 30 years:\n* Monoclonal Gammopathy of uncertain significance -IgM\n* Asymptomatic Waldenström's macroglobulinemia\n* Symptomatic Waldenström's macroglobulinemia\n\nExclusion Criteria:\n\n* Other subtypes of Lymphoproliferative diseases.","ALL","18 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","Waldenström's macroglobulinemia (WM) is a B-cell lymphoproliferative disorder which is defined by bone marrow infiltration by small lymphocytes, lymphoplasmacytoid and plasma cells together with the presence of a detectable monoclonal immunoglobulin M (IgM).The clinical presentation of WM is variable. Symptoms can be related to tumor infiltration, or they can be related to the monoclonal IgM component. The therapeutic options are heterogeneous and there are no well-established in both first line or relapse\u002Frefractory settings. In Spain, the incidence of MGUS-IgM and WM in the last decade is unknown.\n\nThe aims of this retrospective, observational, multicentric study is:\n\n* To develop a national registry of patients diagnosed with Waldenström's Macroglobulinemia and Monoclonal Gammopathy of uncertain significance -IgM in Spain in the past 30years.\n* To evaluate the most relevant clinical characteristics, long-term safety and efficacy of different therapeutic schemes and long-term prognosis of patients with WM\n* To help in the design of future therapeutic strategies, risk prognostic factors and clinical trials in Spain.\n\nMethods:\n\nThe investigators will collect data from the patient clinical files after prior Informed Consent providing from patients with diagnosis of MGUS-IgM and WM in the past 30 years in Spain, according to the WHO classification of lymphoid tumors (2008) revised in 2016. Data from patients not able to provide IC (i.e., already dead patients) will be included only after the permission of the ethics review board.\n\nThe collected data will be included in a database of the Spanish Myeloma and Lymphoma Intergroup (SMALI) team created ad-hoc by the Spanish Society of Hematology and Hemotherapy (SEHH). Each principal investigator in each center will conduct their technical supervision. The evaluation of the treatment protocols will be done following the indications of the intergroup committee according to the guidelines of the International Waldenström's Macroglobulinemia Group.",[25],"Waldenstrom Macroglobulinemia","RECRUITING","2026-02-19",{"date":29,"type":30},"2026-02-23","ACTUAL",{"date":32,"type":30},"2021-10-01",{"date":34,"type":21},"2030-03",{"name":36,"class":37},"Fundación Española de Hematología y Hemoterapía","OTHER",51,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":49,"conditions":50,"keywords":53,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100515517","gammaga-prevalence-of-acid-sphingomyelinase-deficiency-disease-asmd-and-gaucher-disease-in-patients-with-monoclonal-gammopathies-andor-multiple-myeloma-100515517","NCT05992532","GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and\u002For Multiple Myeloma","GammaGA: Study of the Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and\u002For Multiple Myeloma","Inclusion Criteria:\n\n* Adult patients of both sexes.\n* Patients with splenomegaly (spleen palpable at ≥ 1cm from the costal margin) or splenectomy not related to any specific condition, or patients with thrombocytopenia (with or without splenomegaly). In cases where the patient is undergoing treatment for their underlying condition, the thrombocytopenia must have been present prior to the start of the treatment.\n* Patient who gives their consent to participate in the study.\n\nExclusion Criteria:\n\n* Splenomegaly due to portal hypertension (documented by abdominal ultrasound or other instrumental test) due to liver disease\n* Hematologic malignancy \\[documented by positive physical exam + blood smear or fine needle aspiration (FNA) or bone marrow biopsy\\]\n* Hemolytic anemia and\u002For thalassemia\n* Patients who cannot meet the requirements of the protocol due to mental and\u002For cognitive alterations, uncooperative patients, educational limitations and understanding of written language\n* Refusal of the patient to participate in the study","99 Years",{"count":48,"type":21},210,"The study of splenomegaly, and the follow-up of splenectomized patients, is one of the causes of referral of these patients to pediatric gastroenterology and oncohematology clinics, and adult internal medicine and hematology. The study and management of splenomegaly is well described among the different medical specialties to which these patients arrive. After the application of the different algorithms and the different studies that are carried out, these splenomegaly are identified as being of hepatic, infectious, inflammatory, congestive, hematological origin and primary causes. Despite these studies of splenomegaly, approximately 10-15% of these patients still remain undiagnosed.\n\nSeveral studies have suggested that there is an increased frequency of MGUS (monoclonal gammopathy of undetermined significance) and\u002For multiple myeloma (MM) among Gaucher patients. Regarding ASMD (Acid Sphingomyelinase Deficiency), few studies have been published but it seems the 21% of patient with ASMD has MGUS and 15% ASMD patients have MGUS. Moreover, patients with MGUS and Gaucher disease (GD) are at increased risk of developing MM.\n\nThe objective of the present study is to increase the diagnostic sensitivity of these unknown splenomegalys, or unknown splenomegaly patients with MGUS or multiple myeoloma who remain in consultations, using the usual diagnostic clinical procedures of unknown splenomegaly and unknown splenectomy patients, where we include the extraction of a blood sample for dry drop test (DBS), where the determination of the enzymatic\u002Fgenetic activity will be carried out for Gaucher disease (GD) and acid sphingomyelinase deficiency (ASMD) , analysis of LisoGl1 and LisoSM.",[51,52],"Gaucher Disease","Acid SphingoMyelinase Deficiency",[54,55,56,57,58,59,60,61],"Gaucher disease","Acid sphingomyelinase deficiency","GD","ASMD","DBS","Splenomegaly","monoclonal gammopathies","multiple myeloma","2026-02-09",{"date":64,"type":30},"2026-02-11",{"date":66,"type":30},"2023-05-30",{"date":68,"type":21},"2026-05",{"name":36,"class":37},23,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":80,"studyType":22,"phases":4,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},"100586743","resti-registry-spanish-registry-of-primary-immune-thrombocytopenia-and-other-immune-thrombocytopenia-100586743","NCT06919341","RESTI Registry: Spanish Registry of Primary Immune Thrombocytopenia and Other Immune Thrombocytopenia","RESTI","Inclusion Criteria:\n\n* Children as young as 2 months of age and adults in follow-up since 2015 (irrespective of date of diagnosis) with the diagnostic presumption of PIT or other thrombocytopenia of probable immune origin defined as a platelet count \\\u003C 100 x 109\u002FL.\n* Patients who have given written informed consent. In the case of deceased patients, the data will be included in the registry and the investigator will record the impossibility of collecting patient's informed consent form due to death. Only patients deceased after December 31 2015, will be included\n\nExclusion Criteria:\n\n* Patients who, at the investigator's discretion, do not meet the conditions for inclusion in the study","2 Months",{"count":20,"type":21},"1 Year","Primary immune thrombocytopenia (PIT), previously referred to as idiopathic thrombocytopenic purpura, is an acquired disease characterized by accelerated platelet destruction and deficient platelet production by megakaryocytes.\n\nAlthough the existence of PIT has been known for decades, there is no consensus on its triggering mechanisms. On the other hand, this disease presents a very heterogeneous patient profile, both in its characteristics and treatments. In this sense, the diagnosis is still made by excluding other causes of thrombocytopenia.\n\nThere is insufficient epidemiological data on the disease, a fact that is especially evident in our country. We have no data on the incidence or prevalence of this pathology in Spain.\n\nFor all these reasons, this epidemiological study has been designed to increase the available knowledge about this disease and the detailed characterization of the population of patients with ITP in Spain.\n\nThe main objective of this study is to describe the clinical, analytical and treatment characteristics of primary immune thrombocytopenia and other immune thrombocytopenia.\n\nThe study is an epidemiological, ambispective, multicenter study carried out in hospitals in Spain.\n\nInformation will be collected on the disease under study, as well as on the treatments received, using the patient's clinical history as a source document.",[83,84],"ITP - Immune Thrombocytopenia","Primary Immune Thrombocytopenia (ITP)",[86,87,88,89],"ITP","PTI","Trombocitopenia inmune primaria","Primary Inmune Thrombocytopenia","2025-04-07",{"date":92,"type":30},"2025-04-09",{"date":94,"type":30},"2024-09-27",{"date":96,"type":21},"2034-09",{"name":36,"class":37},36,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":46,"enrollmentInfo":107,"targetDuration":109,"studyType":22,"phases":4,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},"100509516","spanish-portuguese-thrombotic-thrombocytopenic-purpura-registry-100509516","NCT05914441","Spanish-Portuguese Thrombotic Thrombocytopenic Purpura Registry","Development Of Spanish-Portuguese Thrombotic Thrombocytopenic Purpura Registry (REPTT): A Study Proposal Of The Spanish Society Of Hematology And Hemotherapy (SEHH) Whit The Portuguese Society Of Hematology (SPH)","RE-PTT","Inclusion Criteria:\n\n1. Patients with diagnosis of TTP according to International Consensus criteria from centres in Spain and Portugal.\n2. Patients that voluntarily sign the informed consent. For subjects unable to provide informed consent, a fully recognized medical authority may be used according to local laws.\n3. Patients between 0 to 99 years old at the time of diagnosis.\n\nNote: Decision was taken to treat the patient with an specific treatment prior and independently of patient inclusion in this non interventional study.\n\nExclusion Criteria:\n\n1. Inability to comply with study procedures and follow-up exams.\n2. Patients with any type of alteration that compromises their ability to grant written informed consent.\n3. Patients that do not consent to participate in the study and do not sign informed consent.\n4. Patients that do not meet the criteria previously mentioned for TTP.",{"count":108,"type":21},300,"3 Years","REPTT is an observational, prospective, multi-country, multicentre and non-interventional registry in which at least 300 patients with Thrombotic thrombocytopenic purpura (TTP) in Spain and Portugal will be evaluated.\n\nThe study will be carried out in the context of the usual clinical practice conditions, not imposing restrictions on the participating physician or influencing their normal clinical practice.",[112],"Purpura, Thrombocytopenic",[114,115,116,117],"registry","Thrombotic thrombocytopenic purpura","real-world","observational","2024-05-27",{"date":120,"type":30},"2024-05-29",{"date":122,"type":30},"2024-03-22",{"date":124,"type":21},"2026-12",{"name":36,"class":37},7,""]